PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

计划入组 6 人 · 首次发布于 2021 年 6 月 28 日

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

计划入组 182 人 · 首次发布于 2023 年 10 月 16 日

Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

计划入组 70 人 · 首次发布于 2021 年 1 月 26 日

PIPE-307

HP-5120

PIPE-791

Johnson & Johnson

United States

TEVA ITALIA SRL

Italy

Rigenerand Srl

Italy

Contineum's JNJ-5120/PIPE-307 Misses Primary Endpoint in Phase 2 MOONLIGHT-1 Depression Trial

J&J's M1 Antagonist PIPE-307 Misses Primary Endpoint in Phase 2 MDD Trial, Second Setback for the Molecule

Contineum Therapeutics On Track for Key Clinical Milestones with PIPE-791 and PIPE-307 Programs